To trigger the cancer immunity cycle, cancer cells at the tumor site generate neoantigens, which are frequently the results of non-synonymous somatic mutations, and present the neoantigens on cell surface through major histocompatibility complex (MHC). This evidence concerns the gene HLA-C and cancer.